Gholam Explores the Phase 3 RATIONALE-301 Study of Sorafenib in HCC
Pierre Gholam, MD, discusses the phase 3 RATIONALE-301 study of frontline tislelizumab vs sorafenib for patients with hepatocellular carcinoma.
Phase 3 Study of Camrelizumab/Rivoceranib Improves PFS and OS Rates in HCC
Pierre Gholam, MD, discusses his thoughts on a phase 3 trial which evaluated camrelizumab plus rivoceranib vs sorafenib in the first-line for patients with unresectable hepatocellular carcinoma.
About the LEAP-002 Trial of Lenvatinib With/Without Pembrolizumab in uHCC
Pierre Gholam, MD, discusses the phase 3 LEAP-002 study of lenvatinib and pembrolizumab for unresectable hepatocellular carcinoma.
An Abundance of Therapies for Early- and Late-Line HCC
Pierre Gholam, MD, discusses standard of care options for hepatocellular carcinoma, including newly-available therapies.
Unresectable HCC: Key Treatment Considerations
A key opinion leader shares clinical practice pearls for the treatment of patients with unresectable HCC.
Unresectable HCC: Unmet Treatment Needs
Pierre Gholam, MD, discusses future directions and novel therapeutic agents for the treatment of unresectable HCC.
IMbrave 150 Trial: Safety and Efficacy Data
Gastroenterology expert, Dr Pierre Gholam, discusses the efficacy and safety data from the phase 3 IMbrave150 trial.
REFLECT Trial: Study Design and Key Data
Dr Gholam reviews the study design and key data from the phase 3 REFLECT trial.
First-Line Treatment in Unresectable HCC
An expert in the treatment of HCC comments on first-line therapeutic options for patients with previously untreated, advanced HCC.
Unresectable HCC: Case Prognosis and Impressions
Dr Gholam, MD, provides expert analysis on the prognosis and treatment of a patient with unresectable HCC.
61-Year-Old Female With Unresectable HCC
Pierre Gholam, MD, presents the case of a 61-year-old woman with hepatocellular carcinoma (HCC).
Future Treatment Landscape for Advanced HCC
Advanced HCC: CELESTIAL Trial
Approaching Second-Line Therapy for Advanced HCC
Advanced HCC: IMbrave150 Trial
Frontline Treatment in HCC: Systemic vs Locoregional Therapy
Multidisciplinary Management and Diagnostic Work-up of HCC
Patient Prognosis of Metastatic HCC
61-Year-Old Man With Stage IV Hepatocellular Carcinoma
A 61-Year-Old Man With Stage 4 Hepatocellular Carcinoma
Pierre Gholam, MD, provides insight on the case of a 61-year-old man with stage 4 hepatocellular carcinoma and evaluates current treatment options on TKIs.
